Sep 21 2009
PLC Systems Inc. (OTC Bulletin Board: PLCSF), a company focused on innovative cardiac and vascular medical device-based technologies, today announced that it will demonstrate its RenalGuard System(TM) at Transcatheter Cardiovascular Therapeutics (TCT) 2009, sponsored by the Cardiovascular Research Foundation, September 21 - 25, 2009, in San Francisco, California. More than 11,000 clinicians and professionals are expected to attend this event.
Dr. Giancarlo Marenzi, Chief, Intensive Cardiac Care Unit, Centro Cardiologico Monzino-University of Milan (CCM), will present interim results of the MYTHOS investigator-sponsored clinical trial of RenalGuard(R) for the first time in the United States. These results were first presented at ESC 2009, the annual meeting of the European Society of Cardiology, in late August in Barcelona, Spain.
In the preliminary results presented at ESC, the trial had enrolled 90 chronic kidney disease (CKD) patients undergoing elective or urgent percutaneous coronary interventions (PCI). Approximately 14.9% of the patients in the control group were determined to have acquired contrast-induced nephropathy (CIN), whereas only 4.6% of those who were treated with RenalGuard acquired CIN. The MYTHOS trial anticipates enrolling a total of 120 patients, and is expected to be completed this year. More information about the trial is available at the company's website: http://www.plcmed.com/Products-Clinical-Investigations2.asp.
The MYTHOS data indicates that patients who were at high risk for renal failure, treated with RenalGuard while undergoing certain imaging procedures, acquired CIN at a significantly lower rate than those who were treated beforehand with overnight hydration. Acquiring CIN has been found to lead to a range of serious and potentially deadly outcomes in patients who already have compromised kidney function.
The investigators for the trial are Dr. Antonio L. Bartorelli, Director, Interventional Cardiology, CCM, and Professor of Cardiology, University of Milan, and Dr. Marenzi, two of the world's leading experts on CIN.
Dr. Bartorelli and Dr. Marenzi will be participating in a "Hot Topics" lunch session, on Friday, September 25, entitled "Chronic Kidney Disease and Contrast Nephropathy: Implications for the PCI Patient." Dr. Marenzi will present "RenalGuard: A New Hydration Method," the first clinical presentation of the MYTHOS study in the U.S. In addition, a poster presentation of the results will be available during the poster session scheduled for Tuesday, September 22 between 8:00 AM - 10:00 PM.
Mark R. Tauscher, president and chief executive officer of PLC Systems, said, "We are extremely pleased that these very positive interim results of the MYTHOS clinical trial are now being presented in the U.S. to a wide range of clinicians and potential partners. These initial results provide strong evidence that RenalGuard could be highly effective in reducing the incidence of CIN in millions of high-risk patients around the world every year. We are also looking forward to Dr. Marenzi's presentation on his experience with RenalGuard, and hope it will help us build on our very successful attendance at ESC by attracting additional interest in our proprietary device."
"Contrast-induced nephropathy is a serious complication resulting from the use of contrast media for coronary and peripheral vascular diagnostic and interventional procedures in high-risk patients," stated Dr. Bartorelli. "These preliminary results indicate that furosemide-induced high urine output with maintenance of intravascular volume through matched hydration can be safely obtained with the RenalGuard System and reduces the risk of CIN in these at-risk patients undergoing imaging procedures."
The MYTHOS trial is a randomized clinical trial designed to provide an assessment of the potential benefits of induced diuresis with automated matched hydration therapy utilizing RenalGuard, compared to standard overnight hydration, in reducing the incidence of CIN in patients with baseline impairment in renal function undergoing cardiac catheterization procedures and percutaneous coronary interventions.
How viral persistence and immune dysfunction drive long COVID